WebFor the quarter ended 31/12/2024, Ionis Pharmaceuticals's revenues decreased by 4.86% and amounted to 152.00M. Net income decreased by 10.66% to -52.00M. Net assets decreased by 3.59% to 573.00M and EPS decreased from -0.33 to -0.37. IONS's Investor Relations. Income Statement Balance Sheet Cash Flow Statement. WebStock analysis for Ionis Pharmaceuticals Inc (IONS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Ionis Pharma Stock Looks Good For The Long Term (NASDAQ:IONS)
Web4 apr. 2024 · Get The Latest IONS Stock Forecast, Price Target, ... Should You Buy or Sell Ionis Pharmaceuticals Stock? Get The Latest IONS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Skip to main content. S&P 500 . DOW . QQQ 320.15. Mullen Automotive Building Momentum With Class-1 Vans. Web31 mrt. 2024 · Company. Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily … in a class there are 18 very tall boys
Ionis Pharmaceuticals Inc IONS Stock Quote - NASDAQ
WebIONIS PHARMACEUTICALS, INC. : Schlusskurs, Intra-day Chart 5 Tage, Veränderung, Volumen, Charttechnische Indikatoren und Orderhistorie der Aktie IONIS ... Web2 apr. 2024 · Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a … WebThe Ionis antisense pipeline. Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 potential first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. in a class there are 18 girls and 14 boys